Kura Oncology
KURA
134 hedge funds and large institutions have $856M invested in Kura Oncology in 2020 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 57 increasing their positions, 35 reducing their positions, and 16 closing their positions.
373% more call options, than puts
Call options by funds: $4.07M | Put options by funds: $859K
117% more capital invested
Capital invested by funds: $395M → $856M (+$461M)
94% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 16
63% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 35
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
13% more funds holding
Funds holding: 119 → 134 (+15)
8.48% more ownership
Funds ownership: 87.68% → 96.16% (+8.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$20M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.3M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$18.2M |
| 4 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$17.5M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$11M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$8.39M |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
-$6.25M |
| 4 |
Millennium Management
New York
|
-$4.56M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$4.24M |
KURA Hedge Fund Activity: Q2 2020 in Review
134 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q2 2020, worth a combined $856M — up 117% from $395M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new KURA positions and 16 closed out — a net gain of 15 holders — while 57 added to existing stakes and 35 trimmed.
The largest buyer was BlackRock, adding an estimated $20M. The largest seller was Prosight Management, cutting an estimated $11M.
- 134 institutional investors held Kura Oncology (KURA) as of Q2 2020, up from 119 in Q1 2020.
- Funds reported $856M of Kura Oncology stock for Q2 2020, up 117% quarter-over-quarter.
- 31 funds opened new Kura Oncology positions in Q2 2020 and 16 closed out, a net change of +15 holders.
- The largest Kura Oncology buyer in Q2 2020 was BlackRock, an estimated $20M added.
- The largest Kura Oncology seller in Q2 2020 was Prosight Management, an estimated $11M sold.
Based on aggregated 13F filings for Q2 2020.